136 related articles for article (PubMed ID: 35184380)
1. CHML is an NRF2 target gene that regulates mTOR function.
Dodson M; Dai W; Anandhan A; Schmidlin CJ; Liu P; Wilson NC; Wei Y; Kitamura N; Galligan JJ; Ooi A; Chapman E; Zhang DD
Mol Oncol; 2022 Apr; 16(8):1714-1727. PubMed ID: 35184380
[TBL] [Abstract][Full Text] [Related]
2. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 Transcription Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY.
Bendavit G; Aboulkassim T; Hilmi K; Shah S; Batist G
J Biol Chem; 2016 Dec; 291(49):25476-25488. PubMed ID: 27784786
[TBL] [Abstract][Full Text] [Related]
4. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway.
Shibata T; Saito S; Kokubu A; Suzuki T; Yamamoto M; Hirohashi S
Cancer Res; 2010 Nov; 70(22):9095-105. PubMed ID: 21062981
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways.
Namani A; Liu K; Wang S; Zhou X; Liao Y; Wang H; Wang XJ; Tang X
Aging (Albany NY); 2019 Dec; 11(24):12600-12623. PubMed ID: 31884422
[TBL] [Abstract][Full Text] [Related]
6. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
7. Histone lysine methyltransferase SETDB2 suppresses NRF2 to restrict tumor progression and modulates chemotherapy sensitivity in lung adenocarcinoma.
Yuan G; Hu B; Ma J; Zhang C; Xie H; Wei T; Yang Y; Ni B
Cancer Med; 2023 Mar; 12(6):7258-7272. PubMed ID: 36504353
[TBL] [Abstract][Full Text] [Related]
8. The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer.
Chen Z; Ye X; Tang N; Shen S; Li Z; Niu X; Lu S; Xu L
Br J Pharmacol; 2014 Jul; 171(13):3196-211. PubMed ID: 24571482
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
10. HAX1 enhances the survival and metastasis of non-small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway.
Liang Z; Zhong Y; Meng L; Chen Y; Liu Y; Wu A; Li X; Wang M
Thorac Cancer; 2020 Nov; 11(11):3155-3167. PubMed ID: 32926529
[TBL] [Abstract][Full Text] [Related]
11. Twist1-mediated 4E-BP1 regulation through mTOR in non-small cell lung cancer.
Lv T; Wang Q; Cromie M; Liu H; Tang S; Song Y; Gao W
Oncotarget; 2015 Oct; 6(32):33006-18. PubMed ID: 26360779
[TBL] [Abstract][Full Text] [Related]
12. Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.
Sun W; Yi Y; Xia G; Zhao Y; Yu Y; Li L; Hua C; He B; Yang B; Yu C; Ye C; Tu F; Chen C; Xu X; Zheng Z; Wang W; Shen X
Mol Ther; 2019 May; 27(5):1039-1050. PubMed ID: 30852137
[TBL] [Abstract][Full Text] [Related]
13. Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non-Small Cell Lung Carcinoma.
Song S; Nguyen V; Schrank T; Mulvaney K; Walter V; Wei D; Orvis T; Desai N; Zhang J; Hayes DN; Zheng Y; Major MB; Weissman BE
Mol Cancer Res; 2020 Dec; 18(12):1777-1788. PubMed ID: 32855269
[TBL] [Abstract][Full Text] [Related]
14. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.
Liu W; Zhao Y; Wang G; Feng S; Ge X; Ye W; Wang Z; Zhu Y; Cai W; Bai J; Zhou X
Redox Biol; 2022 Jul; 53():102344. PubMed ID: 35636015
[TBL] [Abstract][Full Text] [Related]
15. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
[TBL] [Abstract][Full Text] [Related]
16. Regulatory role of KEAP1 and NRF2 in PPARĪ³ expression and chemoresistance in human non-small-cell lung carcinoma cells.
Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
[TBL] [Abstract][Full Text] [Related]
17. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
18. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
19. Emerging roles of Nrf2 signal in non-small cell lung cancer.
Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K
J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479
[TBL] [Abstract][Full Text] [Related]
20. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
